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Defective peroxisome biogenesis with a 
neuromuscular disorder resembling 
Werdnig-Hoffmann disease 
M.R. Baumgartner,  MD; N.M. Verhoeven, PhD; C. Jakobs, PhD; F. Roels, MD; M. Espeel, PhD; 
M. Martinez, MD; D. Rabier, PhD; R.J.A. Wanders, PhD; and J.M. Saudubray, MD 
Article abstract-Objective: Characterization of the defect in a patient presenting a peripheral neuropathy with atypical 
features of distal motor involvement mimicking Werdnig-Hoffmann disease. Patient: Clinical signs included generalized 
hypotonia and floppiness, absence of stretch reflexes, muscle wasting, lack of head control and lingual fasciculations 
associated with unaffected facial muscles, and normal intellectual development. Results: Normal muscle histology ruled 
out Werdnig-Hoffmann disease. Elevated plasma concentrations of very long-chain fatty acids and bile acid intermediates 
combined with normal plasmalogen levels in erythrocytes suggested defective peroxisomal P-oxidation directly demon- 
strated by deficient pristanic acid and partially deficient C26:O was present oxidation in cultured fibroblasts. Severely 
impaired pipecolic acid oxidation in liver and phytanic acid oxidation in fibroblasts was present. On light and electron 
microscopy of the liver tissue, rare peroxisomal membrane ghosts and trilamellar inclusions but absence of peroxisomes 
was noted. Immunoblot analysis revealed absence of peroxisomal P-oxidation enzymes in liver tissue but normal results in 
fibroblasts. Remarkably, expression of the peroxisomal defect in fibroblasts was indicated by the finding of mainly 
cytoplasmatic catalase, as in liver. Preliminary studies excluded classification of this patient within the large PEXl 
complementation group. Conclusions: The results suggest a novel peroxisome biogenesis disorder involving peroxisomal 
P-oxidation as well as phytanic and pipecolic acid oxidation rather than an isolated defect of peroxisomal P-oxidation. The 
association of a clinical picture mimicking Werdnig-Hoffmann disease with a novel peroxisomal disorder raises the 
question of whether investigation for peroxisomal function should be considered in every patient with an enigmatic spinal 
muscular atrophy-like syndrome. 
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Most patients with inherited peroxisomal disorders 
present with severe disturbances of the nervous sys- 
Usually they are detected easily by additional 
clinical symptoms, such as errors of morphogenesis 
including dysmorphia and skeletal abnormalities, 
neurosensory defects, o r  hepatodigestive involve- 
ment. These three main early infantile categories of 
clinical symptoms roughly correspond to the original 
clinical descriptions, namely Zellweger syndrome 
(ZS), which is the most severe disorder combining all 
characteristic symptoms; neonatal adrenoleukodys- 
trophy (NALD), which has a predominantly neuro- 
logic presentation; and infantile Refsum disease, 
which is the least  severe disorder with predominance 
of hepatodigestive symptoms.1.2 Biochemically, they 
are characterized by the  loss of multiple peroxisomal 
functions and absence of morphologically distin- 
guishable peroxisomes in hepatocytes and renal tu-  
symptoms but have an impairment of only a single 
or several peroxisomal functions and usually the 
presence of hepatic peroxisomes.lz 
In this report, we describe a unique patient pre- 
senting a peripheral neuropathy with atypical fea- 
tures of distal  motor involvement mimicking 
Werdnig-Hoffmann disease that was later revealed 
as an original peroxisome biogenesis disorder. 
Case report. This female child was born a t  term to eon- 
sanguineous parents of Algerian origin after an uneventful 
pregnancy. Her weight was 3.2 kg, and Apgar scores were 
normal. Global hypotonia and moderate jaundice were 
noted. She was hospitalized several times in another hos- 
pital because of severe hypotonia and was then transferred 
to our hospital a t  the age of 5 months. She presented with 
severe generalized hypotonia and floppiness with predomi- 
nant involvement of axial and distal muscles. The scarf 
bule cells1,2 or peroxisome mosaicism.3 Other sign was positive. Tendon stretch reflexes were absent, 
peroxisomal disorders may  present with s imilar  and there was severe muscle wasting. No pyramidal tract 
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signs were found. She lacked head control but had good 
eye contact, was alert, and smiled upon stimulation. No 
dysmorphia was noted. Lingual fasciculations were con- 
stantly present. The girl showed normal awareness and 
mental development (determined by the Brunet-Lezine 
scale for psychomotor development in childhood). Given 
the clinical picture, Werdnig-Hoffmann disease was con- 
sidered. Serum creatine kinase was normal. Nerve conduc- 
tion velocity was within normal limits for age. EMG 
showed typical neurogenic changes predominantly in distal 
muscles with an  increase in amplitude and duration of 
the motor unit potentials and an  excess of polyphasic po- 
tentials. However, muscle histology was normal, and 
Werdnig-Hoffmann disease was ruled out. 
In a more comprehensive evaluation, moderate hepato- 
megaly and impaired liver function reflected in elevated 
transaminases (aspartate aminotransferase 136 IU/L, ala- 
nine aminotransferase 155 IUL;  normal 5 to 20 for both 
values), prolonged prothrombin time (46%), and lowered 
coagulation factors (factor I1 71%, factors VII + X 5276, 
factor V 87%) were found. Hypocholesterolemia (total cho- 
lesterol 2.15 mmol/L, normal 3.25 to 6.3; HDL cholesterol 
0.26 mmol/L, normal >0.85; LDL cholesterol 1.53 mmol/L, 
normal 3.3 to 4.1) and lowered levels of plasma vitamin E 
(3.6 mg/L, normal 8 to 12) were present. An initial meta- 
bolic screening showed an  abnormal organic acid profile 
with dicarboxylic aciduria suggesting a mitochondria1 fatty 
acid oxidation defect, which was later ruled out (normal 
oxidation in fibroblasts). Chromatography of plasma and 
urine amino acids revealed an  elevated pipecolic acid level 
and led to a complete peroxisomal investigation. A liver 
biopsy specimen showed mild periportal fibrosis associated 
with beginning neocanalicular proliferation and mild ste- 
atosis. On ophthalmologic examination bilateral cataracts 
were noted. Cerebral MRI, EEG, electroretinogram, and 
visual evoked potentials were normal at that time. Plasma 
vitamin A, total and free carnitine, and routine laboratory 
studies of red and white blood cells and electrolytes were 
within normal limits. 
At 11 months she could sit, pass objects from one hand 
to the other, and pronounce several words. According to 
the peroxisomal investigation (table 1) and given the prob- 
able role of docosahexaenoic acid (DHA) in the pathogene- 
sis of peroxisome biogenesis d i ~ o r d e r s , ~  a treatment with 
DHA (100 mgh,  later 200 mg/24 h) and a diet low in 
phytanic acid was started. However, major hypotonia with 
severe amyotrophy persisted, and progressive psychomotor 
retardation began. At 15 months strabismus and retinitis 
pigmentosa with abnormal electroretinogram were noted. 
Hearing remained normal. Skeletal radiography showed 
severe osteoporosis. At 27 months she went on a holiday to 
Algeria where DHA treatment was stopped. She had a 
severe gastrointestinal infection with dehydration, loosing 
almost 2 kg of weight and deteriorating rapidly. Coming 
back to Paris she was hospitalized close to her home and 
later transferred to our hospital. On admittance she was in 
a severely deteriorated state, especially for cognitive func- 
tions. After an  initial recovery she suddenly died without 
explanation. No autopsy was performed. 
Methods. Very long-chain fatty acids (VLCFAs); phy- 
tanic, pristanic, and pipecolic acid; and bile acid intermedi- 
ates were measured in plasma according to previously 
described  method^.^ Polyunsaturated fatty acids and plas- 
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malogens were measured by capillary column gas chroma- 
tography after direct transesterification of plasma and 
erythrocytes, as specified elsewhere.fi 
Liver and skin biopsies were performed for diagnostic 
purposes after informed consent of the parents. Peroxiso- 
ma1 functions were determined in cultured fibroblasts by 
assaying phytanic a-~xidat ion,~ peroxisomal P-oxidation, 
dihydroxyacetone phosphate acyltransferase (DHAPAT) 
activity, de novo plasmalogen synthesis, and concentra- 
tions of VLCFAs as previously Cross-reactive 
immunologic material to the peroxisomal p-oxidation 
enzymes acyl-CoA oxidase and 3-oxoacyl-CoA thiolase in 
fibroblasts and liver tissue was examined by an immuno- 
blotting procedure as described by Wanders et  al.ll 
L-pipecolic acid oxidation was investigated in liver as de- 
scribed by Wanders et  a1.12 
Peroxisomes were made visible in the liver tissue for 
light and electron microscopy by staining for catalase ac- 
tivity13 and by protein A-colloid gold immunolocalization of 
the matrix proteins catalase, acyl-CoA oxidase, 3-ketoacyl- 
CoA thiolase, and alanine/glyoxylate aminotransferase 
(AGT), as well as 43-kd peroxisomal membrane ~ r 0 t e i n . I ~  
Morphometry of peroxisomes was performed on random 
electron micrographs with a semi-automated device.15 
The cultured skin fibroblasts were fused essentially ac- 
cording to Brul et  al.16 The fused cells were cultured for 3 
days on minimum essential medium (DMEM) without fetal 
calf serum (FCS), after which the occurrence of comple- 
mentation was tested with pristanic acid p-oxidation.8 
Results. The results of biochemical analyses reflecting 
peroxisomal metabolism in this patient are given in table 
1. The increased levels of VLCFAs and bile acid intermedi- 
ates combined with an elevated pristaniclphytanic acid ra- 
tio and normal plasmalogen levels in erythrocytes pointed 
to a disorder of peroxisomal P-oxidation, as directly demon- 
strated by deficient pristanic acid and partially deficient 
C26:O p-oxidation in cultured fibroblasts (see table 1). In 
addition, pipecolic acid was highly elevated in plasma (but 
not in urine) due to severely impaired pipecolic acid oxida- 
tion in liver tissue (see table 1). As expected, de novo 
plasmalogen synthesis and DHAPAT activity in fibroblasts 
were normal (see table 1). Immunoblotting studies in liver 
tissue showed absence of the 50-kd and 20-kd components 
of acyl-CoA oxidase and 41-kd thiolase, whereas in fibro- 
blasts normal results were found (table 2). Remarkably, 
virtually all catalase was cytoplasmatic, indicating that 
the peroxisomal defect was indeed expressed in fibroblasts. 
Light and electron microscopy of the liver tissue dis- 
closed absence of peroxisomes with cytoplasmic and nu- 
clear localization of catalase and AGT (figure 1). Very rare 
peroxisomal membrane ghosts with the approximate size 
of normal peroxisomes were identified by their immunore- 
activity for a 43-kd peroxisomal membrane protein (elec- 
tron micrograph of such an  organelle in reference 14, 
figure 7). Sometimes these membranes formed double or 
triple layers, enclosing little or no contents. Many fine 
insoluble fat droplets were present in nonparenchymal 
cells together with small birefringent inclusions. Enlarged 
periodic-acid-Schiff- and acid phosphatase-positive macro- 
phages were found. There was massive fatty infiltration in 
the parenchyma, and beginning cirrhosis was seen. By 
electron microscopy typical trilamellar inclusions were 
found in parenchymal and nonparenchymal cells (figure 2). 
Table 1 Biochemical analysis reflecting perorisomal disorder 
Zellweger 
Parameter Patient Controls syndrome 
Plasma 
C,,:, (wnoVL) 4.21 0.22-1.31 1.18-1.77 
C26:o/C22:o ratio 0.25 0.003-0.021 0.056-0.76 
Trihydroxycholestanoic acid (KrnoVL) 0.48 0-0.035 0.1 1-47.2 
0.32-44.1 Dihydroxycholestanoic acid (pmoVL) 1.414 0-0.0 12 
Pipecolic acid (kmol/L) 346 0.54-2.46 7.53 -391 
Phytanic acid (FmoVL) 36.2 0.01-9.88 0.52 -118 
Pristanic acid (FmoVL) 20.6 0.01-2.98 0.10-34.7 
Pristanic acidlphytanic acid ratio 0.57 0.05-0.40 0.08-0.44 
Docosahexaenoic acid (DHA) (PrnollL) 20.66 94.09 ? 36.64 NA 
Plasmalogens (pmol/L) 25.84 69.13 2 30.95 NA 
Urine 
Pipecolic acid (mmoVmol creatinine) 20 1.2-24.1 20.2-270 
Erythrocytes 
DHA (prnoV10‘ cells) 7.47 37.78 t 13.59 NA 
Plasmalogens (pmoVW cells) 38.77 54.72 t 6.26 NA 
Fibroblasts 
De novo plasmalogen biosynthesis 
% pPE in PE 88.3 64.5-85.7 4.6-55.4 
0.4-1.2 % pPC in PC 9.2 
6.4-63.1 “W14C-ratio in alkenyl PE 1.6 0.3-2.4 
3H/14C-ratio in alkenyl PC 0.6 0.3-2.0 3.1-10.9 
2.0-8.0 
DHAP-AT (nmoV2 hr/mg) 10.2 5.9-15.9 0-1.6 
C26:O (kg/mg protein) 0.14 0.02-0.10 0.21-1.21 
C26:0/C22:0 ratio 0.07 0.03-0.07 0.21-1.07 
C26:O P-oxidation (pmoVmidmg protein) 381 1,002 t 336 117 i- 82 
Pristanic acid P-oxidation (pmoVmidmg protein) 61 1,147 ? 325 12 t 12 
Phytanic acid a-oxidation (pmol/min/mg protein) 10.2 68 2 13 < 10 
Catalase immunofluorescence Diffuse Particle bound Diffuse 
Liver 
Pipecolic acid oxidation (pmolklmg protein) 14 400 ? 38 <1 
Values are represented as means 2 SD or as ranges. 
NA = not available; pPE = plasmalogen phosphatidylethanolamine; PE = total phosphatidylethanolamine; pPC = plasmalogen phos- 
phatidylcholine; PC = total phosphatidylcholine; DHAP-AT = dihydroxyacetone phosphate acyltransferase. 
Preliminary complementation studies to establish the 
genetic relationship between our patient and other peroxi- 
soma1 disorders revealed that our patient does not belong 
to the large complementation group with P E X l  defi- 
c i e n ~ y . ~ ~ J ~  Further complementation studies to classify our 
patient are under way (see Note added in proof). 
Discussion. The rapid expansion of the clinical 
spectrum of peroxisome-related diseases constitutes 
a widening diagnostic ~ h a l l e n g e . ~ ~ ’ ~  According to 
recent recommendations, biochemical investigation 
of peroxisomal functions is warranted if a patient 
has one or more of the following abnormalities: 
craniofacial, neurologic (hypotonia, seizures, periph- 
eral neuropathy), neurosensory (visual or hearing 
abnormalities), hepatic, skeletal, and digestive with 
hypocholesterolemia and failure to The re- 
ported patient presented with a neurologic picture 
strikingly similar to Werdnig-Hoffmann disease and 
initially did not arouse suspicion of peroxisomal 
disease. Typical clinical symptoms of Werdnig- 
Hoffmann disease included generalized hypotonia 
and floppiness, absence of stretch reflexes, muscle 
wasting, lack of head control and lingual fascicula- 
tions associated with unaffected facial muscles, and 
normal intellectual development.21 The neurogenic 
changes in EMG studies as well as normal serum 
creatine kinase were compatible with the diagnosis 
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Table 2 Immunohlotting studies on cultured fibroblasts and 
liver tissue 
Fibroblasts Liver tissue 
. ~ _ _ _  
Protein studied Patient Control Patient Control 
~~ 
Acyl-CoA oxidase 
70 kd + + + + 
50 kd + + 
20 kd + + 
+ 
+ 
- 
- 
3-oxoacyl-CoA thiolase 
41 kd 
44 kd 
of Werdnig-Hoffmann disease. However, our patient 
had involvement of predominantly distal muscles 
rather than proximal and axial muscles, as is most 
commonly observed in Werdnig-Hoffmann disease. 
Furthermore she later learned to  sit and control her 
head, whereas patients with early onset Werdnig- 
Hoffmann disease usually show progressive worsening 
Figure 2. Electron micrograph showing equidistant (rig- 
id) trilamellar inclusions (arrowheads) in a liver paren- 
chymal lysosome, which also contains insoluble fat 
droplets (asterisk). Scale bar = 0.2 pm; magnification 
X45,OOO. 
Figure 1. Diffuse cytoplasmatic localization of alaninel 
glyoxylate aminotransferase in the liver parenchymal cells; 
also, many parenchymal nuclei are immrtnoreactive. Gran- 
ules indicating a peroxisomal localization of the antigen 
are not observed; nonparenchymal tissue (asterisk) shows 
no reaction. A similar localization was found for catalase, 
reflecting the typical distribution of peroxisome biogenesis 
disorders. Magnification X400. 
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of neurologic symptoms and die early.21 Conversely, 
mental development had slowed down in our patient 
at the age of 1 year, whereas in Werdnig-Hoffmann 
disease intelligence is preserved. Finally, other clini- 
cal features unusual for Werdnig-Hoffmann disease 
such as cataracts and hepatopathy were present, 
raising serious doubts as to  this diagnosis. Normal 
morphology of muscle definitely ruled out Werdnig- 
Hoffmann disease. 
The unique finding in our patient is that accu- 
mulation of VLCFAs and bile acid intermediates 
combined with normal plasmalogen levels in erythro- 
cytes point t o  an isolated defect of peroxisomal 
P-oxidation. Conversely, absence of genuine liver 
peroxisomes, accumulation of trilamellar inclusions, 
and deficient phytanic and pipecolic acid oxidation 
suggest a peroxisome biogenesis disorder (table 3). 
A generalized peroxisomal disorder such as classic 
ZS or NALD is excluded by the finding of normal 
plasmalogen levels in erythrocytes and normal de 
novo plasmalogen synthesis and DHAPAT activity in 
fibroblasts. I t  is tempting to  explain this normal 
plasmalogen synthesis by the presence of rare but 
normally sized peroxisomal membrane ghosts in the 
liver; indeed the enzymes involved are membrane- 
bound. However, the increased plasma concentra- 
tions of VLCFAs and bile acid intermediates 
Table 3 Current scheme of peroxisomal defects 
Zellweger syndrome 1 Patient J. Isolated P-oxidation disorder 
VLCFAs t T t 
Bile acids T t N- t 
Pipecnlic acid T t N 
Phytanic acid 
Pristanic acid 
T 
T 
t 
t 
N- t 
1' 
Pristaniclphytanic N t 9 
Plasmalogens i N N 
Liver peroxisomes on microscopy Absent Absent Present 
Molecular defect 
Other examples 
Biogenesis disorder: Biogenesis disorder: Single enzyme defect: loss of a 
generalized loss of loss of multiple single peroxisomal function 
peroxisomal functions peroxisomal functions 
lnfantile Refsum Rhizomelic chondro- Refsum disease, X-linked ALD 
disease, neonatal ALD dysplasia punctata 
VLCFAs = very long-chain fatty acids; N = normal; ALD = adrenoleukodystrophy. 
combined with an elevated pristanidphytanic acid 
ratio are suggestive of a defect in peroxisomal 
P-oxidation, as directly demonstrated by deficient 
pristanic and partially deficient C26:O P-oxidation in 
cultured fibroblasts. The elevation of bile acid inter- 
mediates in our patient is an important clue to the 
site of a possible defect because normal concentra- 
tions of bile acid intermediates were found in two 
siblings with isolated acyl-CoA oxidase deficiency,2z 
whereas they were abnormal in isolated deficiencies 
of peroxisomal bi(trilfunctiona1 proteinz3 and peroxi- 
somal t h i o l a ~ e . ~ ~  
Apart from these well-characterized patients, an 
increasing number of patients have been described 
with a defect in peroxisomal p-oxidation of unknown 
etiology and detectable enzyme  protein^.^^^^^^^ Most 
were considered to have an enzyme protein without 
catalytic activity. However, in contrast to  these pa- 
tients, liver peroxisomes in our patient were ultra- 
structurally not distinguishable after staining for 
marker enzymes, peroxisomal P-oxidation proteins 
were absent on immunoblot analysis, and pipecolic 
acid oxidation was impaired, all of which is in favor 
of a generalized peroxisomal disorder (see table 3). 
The enzymatic organization of the peroxisomal fatty 
acid P-oxidation pathway remains incompletely un- 
derstood. There are two acyl-CoA oxidases with spec- 
ificity for straight-chainZ6 and branched-chain fatty 
acyl-CoA esters.27 The view that the subsequent 
steps are catalyzed by one bifunctional protein and 
one peroxisomal thiolase is no longer tenable.28 Re- 
cently, Wanders et al.29 provided evidence that there 
are separate pathways for the oxidation of straight- 
chain and branched-chain fatty acids. The findings of 
severely deficient pristanic acid P-oxidation and less 
severe deficiency of C26:O P-oxidation suggest a de- 
fect in the pathway of branched-chain rather than 
straight-chain fatty acids in the present case. 
The expression in fibroblasts in our patient is bi- 
zarre; although immunoblot analysis showed the 
presence of acyl-CoA oxidase and 3-oxoacyl-CoA thio- 
lase enzyme proteins, deficient pristanic acid and 
partially deficient C26:O P-oxidation with a mildly 
abnormal VLCFA profile were found, indicating that 
at least one of the peroxisomal P-oxidation enzymes 
must be immunologically intact but catalytically in- 
active. Remarkably, virtually all catalase was cyto- 
plasmatic, indicating that the peroxisomal defect 
was definitely expressed in fibroblasts. Differences 
between cultured fibroblasts and a liver sample have 
been reported in other peroxisomal patients.3 
The findings in our patient are different from 
those for any of the patients described in the litera- 
ture so far, and it is difficult to  know what the ac- 
tual defect is. Overall, the results suggest a disorder 
of peroxisome biogenesis involving peroxisomal 
P-oxidation, phytanic acid a-oxidation, and pipecolic 
acid oxidation rather than an isolated defect of per- 
oxisomal P-oxidation. However, the scheme of per- 
oxisomal p-oxidation as used today may be too 
simplistic, and more enzymes may yet be identified. 
Additional studies are under way to reveal the un- 
derlying defect in our patient. 
Whatever the basic defect is, we stress that prena- 
tal diagnosis is possible in such undefined peroxi- 
somal disorders. Indeed, prenatal diagnosis was suc- 
cessfully made in a younger, healthy brother of the 
present patient by measuring VLCFAs and bile acid 
intermediates in amniotic 
Returning to the clinical aspects, we emphasize 
that in our patient elevated pipecolic acid on screen- 
ing amino acid chromatography finally led to  a com- 
plete peroxisomal investigation that revealed the 
unique peroxisomal disorder. DHA treatment re- 
sulted in only minor biochemical improvement (re- 
sults not shown) and no clinical improvement. The 
association of DHA ethyl ester with a very low phy- 
tanic acid diet may have influenced the potential of 
DHA in our patient by neutralizing its  effect^.^ Given 
that the interruption of DHA therapy coincided with 
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a severe intermittent illness (gastroenteritis and de- 
hydration), a deleterious effect of this interruption in 
our patient seems rather unlikely, but cannot be 
ruled out. 
The association of a clinical picture mimicking 
Werdnig-Hoffmann disease with an original peroxi- 
soma1 disorder raises the question of whether in- 
vestigation for peroxisomal function should be 
considered in every patient with an enigmatic 
spinal muscular atrophy-like syndrome. 
Note added in proof. Complementation studies 
have now shown that the gene affected in this pa- 
tient is the PEXl2 gene, which is one of many differ- 
ent genes involved in peroxisomal biogenesis 
mutated in one of the complementation group ((263). 
See Reference 30. 
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